ArticleEClinicalMedicine2023

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).

Urban Novak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.